Literature DB >> 10615237

Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.

O Johannsson1, N Loman, T Möller, U Kristoffersson, A Borg, H Olsson.   

Abstract

We investigated cancer incidence between 1958 and 1995 in 1873 individuals belonging to 29 consecutively identified BRCA1 and 20 BRCA2 associated families from Southern Sweden using data from parish and local tax authorities, as well as the Swedish Cancer Registry, Cause of Death Registry and Census Registry. 150 malignant tumours were analysed from 1145 relatives in the BRCA1 families and 87 tumours were analysed from 728 relatives in the BRCA2 families. After excluding index cases which led to the mutation analysis, the incidence for all malignant tumours was significantly increased for both BRCA1- standardised morbidity rate, SMR, 1.98, 95% confidence interval (CI) 1.59-2.45; P < 0.0001 and BRCA2- (SMR 1.79, 95% CI 1.35-2.31; P < 0.0001) associated family members. For women in BRCA1-associated families, the incidence of breast cancer (SMR 3.76, 95% CI 2.29-5.80, P < 0.0001), ovarian cancer (SMR 15.49, 95% CI 9.46-23.92, P < 0.0001), stomach cancer (SMR 5.86, 95% CI 1.60-15.01, P = 0.005) were significantly increased. Amongst men only invasive squamous cell cancer of the skin was significantly increased (SMR 6.02, 95% CI 1.96-14.05, P = 0.002). In BRCA2 associated families, female breast cancer (SMR 3.03, 95% CI 1.61-5.18, P = 0.0005) was increased after exclusion of index cases. If these were included, ovarian cancer (SMR 5.16, 95% CI 1.89-11.24, P = 0.001), invasive cervical cancer (SMR 4.21, 95% CI 1.15-10.79, P = 0.016), male breast cancer (SMR 290.52, 95% CI 125.42-572.43, P < 0.0001), and prostate cancer (SMR 2.21, 95% CI 0.89-4.56, P = 0.042) were significantly increased. The increased risk for ovarian cancer in BRCA2 related families were limited to the cases leading to mutation analysis. Our data suggest that apart from breast and ovarian cancer, the incidence of other cancer types do not appear to be greatly increased in BRCA1- and BRCA2-associated families and does not warrant specific clinical follow-up in carriers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10615237     DOI: 10.1016/s0959-8049(99)00135-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  34 in total

1.  Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer.

Authors:  Si-Yi Hu; Tao Liu; Zhen-Zhen Liu; Elisa Ledet; Cruz Velasco-Gonzalez; Diptasri M Mandal; Shahriar Koochekpour
Journal:  Asian J Androl       Date:  2010-02-22       Impact factor: 3.285

2.  BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.

Authors:  Bernard Friedenson
Journal:  MedGenMed       Date:  2005-06-29

3.  Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.

Authors:  Haley Streff; Jessica Profato; Yuanqing Ye; Denise Nebgen; Susan K Peterson; Claire Singletary; Banu K Arun; Jennifer K Litton
Journal:  Oncologist       Date:  2016-06-15

4.  Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Authors:  Rong Na; S Lilly Zheng; Misop Han; Hongjie Yu; Deke Jiang; Sameep Shah; Charles M Ewing; Liti Zhang; Kristian Novakovic; Jacqueline Petkewicz; Kamalakar Gulukota; Donald L Helseth; Margo Quinn; Elizabeth Humphries; Kathleen E Wiley; Sarah D Isaacs; Yishuo Wu; Xu Liu; Ning Zhang; Chi-Hsiung Wang; Janardan Khandekar; Peter J Hulick; Daniel H Shevrin; Kathleen A Cooney; Zhoujun Shen; Alan W Partin; H Ballentine Carter; Michael A Carducci; Mario A Eisenberger; Sam R Denmeade; Michael McGuire; Patrick C Walsh; Brian T Helfand; Charles B Brendler; Qiang Ding; Jianfeng Xu; William B Isaacs
Journal:  Eur Urol       Date:  2016-12-15       Impact factor: 20.096

5.  Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study.

Authors:  Ilir Agalliu; Erika M Kwon; Claudia A Salinas; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Causes Control       Date:  2009-11-10       Impact factor: 2.506

6.  Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.

Authors:  Vladimir M Moiseyenko; Nikita M Volkov; Evgeny N Suspistin; Grigoriy A Yanus; Aglaya G Iyevleva; Ekatherina Sh Kuligina; Alexandr V Togo; Alexandr V Kornilov; Alexandr O Ivantsov; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

7.  Risk of colorectal adenomas in women with prior breast cancer.

Authors:  Ashish Shukla; Sandhya Shukla; Ayodele Osowo; Terry Mashtare; Manoop S Bhutani; Sushovan Guha
Journal:  Dig Dis Sci       Date:  2012-10-12       Impact factor: 3.199

8.  Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.

Authors:  Ilir Agalliu; Robert Gern; Suzanne Leanza; Robert D Burk
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

9.  Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer.

Authors:  Ava Kwong; L P Wong; H N Wong; F B F Law; E K O Ng; Y H Tang; W K Chan; D T K Suen; C Choi; L S Ho; K H Kwan; M Poon; T T Wong; K Chan; S W W Chan; M W L Ying; W C Chan; E S K Ma; J M Ford; D W West
Journal:  Hugo J       Date:  2010-04-10

10.  Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis.

Authors:  Jeffrey C Francis; Afshan McCarthy; Martin K Thomsen; Alan Ashworth; Amanda Swain
Journal:  PLoS Genet       Date:  2010-06-24       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.